For better monitoring of tumor molecular changes, liquid biopsy is emerging as a more convenient and potentially lower-cost alternative to tissue biopsy. Liquid biopsy detects genetic aberrations in circulating tumor cells and deoxyribonucleic acid from apoptotic and necrotic tumor cells.
Jason (Gang) Jin
Jason (Gang) Jin (jason.jin@ cloudhealth99.com) is a member of the National Thousand Talents Program in China; founder and chief executive officer (CEO) of Cloud- Health Genomics, Ltd., and CloudHealth Medical Group, Ltd.; chair and CEO of ShanghaiBio Corporation; cofounder and founding director of the National Engineering Center for Biochip at Shanghai (Shanghai Biochip Co. Ltd); and cofounder and founding CEO of Shanghai Biotechnology Corporation. Dr. Jin is also an adjunct professor at the Shanghai Institutes of Biological Sciences, the Chinese Academy of Sciences, Fudan University, and Shanghai Jiaotong University. He received his Ph.D. and postdoctoral fellow degrees in biology from the University of California, San Diego. He graduated from the School of Medicine, Fudan University (Shanghai Medical University, China). Dr. Jin also attended the intensive MBA program at Rutgers, the State University of New Jersey, United States.